MedBright AI Investments Azioni (OTC: MBAIF)

Ultime notizie per MedBright AI Investments (OTC:MBAIF) Azioni

MedBright AI Investments Inc is a capital allocator focusing on investing in healthcare technology companies.

MEDBRIGHT AI INVTS INC by MEDBRIGHT AI INVTS INC.

MedBright AI Investments Inc

Needham analyst Scott Berg reiterates Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Buy and maintains $300 price target.

News

Price Target

Reiteration

Analyst Ratings

WDAY

Needham Reiterates Buy on Workday, Maintains $300 Price Target

Freightos Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>), a leading vendor-neutral digital booking and payment platform for the international freight industry, today announced that Ran Shalev, Chief Financial Officer, has decided to conclude his tenure effective December 31, 2024, to pursue another role. The company is in the process of a search for a successor. In order to ensure continuity, Mr. Shalev has agreed following his departure to actively assist with ongoing operations and with handover throughout Q1.
&nbsp;
Mr. Shalev has served as Freightos' CFO since 2016, overseeing the company's financial operations during a transformative period that included its public listing on Nasdaq, the successful execution of multiple strategic acquisitions, and consistent growth in revenue and transaction volumes.

Management

CRGO

Freightos To Deaprt As CFO Effective December 31 To Pursue Another Job, Company In Process Of Finding A Successor

<ul>
<li>Amglidia is a proprietary, patented liquid product that was developed for the treatment of neonatal diabetes mellitus by AMMTeK, a French biotechnology company. The product was approved by the EMA in 2018.&nbsp;</li>
<li>The product has already been granted Orphan Drug Designation by the U.S. FDA. Neonatal diabetes mellitus is a rare condition estimated to impact approximately 300 patients in the United States.&nbsp;</li>
<li>Currently, there are no FDA-approved oral treatment options and as a result, U.S. patients frequently either rely on compounded products that are not FDA-approved or administer products off-label by making homemade suspensions.</li>
<li>AMMTeK has conducted a post-approval study tracking five years of real-world safety and efficacy in European patients, which will be used to support Eton's NDA submission. Eton plans to hold a meeting with the FDA in the first quarter of 2025 and anticipates submitting an NDA for the product in 2026.</li>
</ul>

Health Care

General

ETON

Eton Pharmaceuticals Has Acquired The Us Rights To Amglidia (Glyburide Oral Suspension, Known As Glibenclamide In Europe) For Neonatal Diabetes Mellitus From AMMTeK, Potential US Marketing Application Submission Expected In 2026

Loop Capital analyst Garik Shmois downgrades Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) from Buy to Hold and maintains the price target from $315 to $315.

Downgrades

Loop Capital Downgrades Eagle Materials to Hold, Maintains Price Target to $315

Wolfe Research analyst Andrew Rosivach upgrades Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) from Peer Perform to Outperform and announces $353 price target.

Upgrades

Wolfe Research Upgrades Jones Lang LaSalle to Outperform, Announces $353 Price Target

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO&#x2A; Group 1) functional class (FC) III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours). In the study, WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, both on top of background PAH therapy. Based on the strength of these results, an independent data monitoring committee has recommended ZENITH be stopped early and all participants be offered the opportunity to receive WINREVAIR through the SOTERIA open-label extension study. In preliminary assessment, adverse events and serious adverse events were balanced between the treatment groups.
"PAH is a serious, progressive disease with a high incidence of morbidity and mortality," said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "Based on the primary endpoint demonstrating overwhelming efficacy, all ZENITH study participants will be offered the opportunity to receive WINREVAIR. These findings are impressive, set a high evidentiary bar for studies of future candidates developed for the treatment of PAH and support the potential of WINREVAIR to be practice-changing in the management of PAH."
"The ZENITH trial was designed to evaluate whether the addition of WINREVAIR, an activin signaling inhibitor, could reduce the risk of death, lung transplantation, or PAH hospitalizations for patients living with advanced PAH," said Dr. Vallerie McLaughlin&#x2A;&#x2A;, Kim A Eagle MD Endowed Professor of Cardiovascular Medicine and Director, Pulmonary Hypertension Program, University of Michigan in Ann Arbor. "This is the first study in PAH in which the interim analysis led to an early conclusion of the study due to overwhelming efficacy. WINREVAIR has brought significant optimism to the field, and we thank the investigators and patients for being part of this important study."
WINREVAIR is currently approved in the U.S. and 36 countries based on the results from the Phase 3 STELLAR trial. Most recently, in November of this year, WINREVAIR was submitted for approval in Japan based on the STELLAR trial and results from an open-label Phase 3 study in Japanese patients.
Results from ZENITH will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

Merck's WINREVAIR Achieves Results in PAH Study, Trial Ends Early on Efficacy

Wolfe Research analyst Andrew Rosivach downgrades Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) from Outperform to Peer Perform.

NMRK

Wolfe Research Downgrades Newmark Group to Peer Perform

Barclays analyst Ramsey El-Assal initiates coverage on MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Equal-Weight rating and announces Price Target of $27.

Initiation

MARA

Barclays Initiates Coverage On MARA Holdings with Equal-Weight Rating, Announces Price Target of $27

Barclays analyst Lydia Rainforth upgrades Equinor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Equal-Weight to Overweight.

EQNR

Barclays Upgrades Equinor to Overweight

EnLink Midstream, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) shares traded higher premarket on Monday after it disclosed a merger deal with ONEOK, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) for $4.3 billion.
As per the deal, each EnLink common unit not owned by ONEOK will be exchanged for <a target="_blank" href="https://www.benzinga.com//node/42155913" rel="noreferrer noopener">0.1412 shares of ONEOK stock.</a>
This exchange ratio reflects EnLink&#8217;s closing price of $15.75 on November 22, 2024, divided by ONEOK&#8217;s 10-day volume-weighted average price (VWAP).
ONEOK will issue approximately 37 million shares, representing about 6% of its total shares outstanding after the transaction.
ONEOK, which holds approximately 44% of EnLink&#8217;s common units, has committed to voting in favor of the transaction.
The transaction, subject to customary closing conditions, is expected to close in the first quarter of 2025.
The merger&#8217;s completion requires approval from a majority of EnLink&#8217;s outstanding common units, including those owned by ONEOK, and satisfaction of other customary closing conditions.
Pierce H. Norton II, ONEOK president and chief executive officer, said, &#8220;This tax-free transaction to acquire the remaining outstanding EnLink units is expected to be accretive to ONEOK shareholders and provide EnLink unitholders with significantly greater trading liquidity and an attractive dividend yield.&#8221;&nbsp;&nbsp;
In October 15, 2024, ONEOK disclosed the successful completion of its acquisition of Global Infrastructure Partners&#8217; (GIP) entire interest in EnLink for a total cash <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40626128/oneok-spends-3b-on-enlink-midstream-stake-2-6b-on-medallion" rel="noreferrer noopener">consideration of approximately&nbsp;$3.3 billion</a>.
Investors can gain exposure to the OKE stock via&nbsp;Global X MLP &amp; Energy Infrastructure ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLPX#NYSE">MLPX</a>) and Tortoise North American Pipeline ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPYP#NYSE">TPYP</a>).
Price Action: ENLC shares are up 1.27% at $15.95 premarket at the last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42118286/7-us-natural-gas-stocks-to-watch-as-henry-hub-prices-surge-50-in-november" target="_blank" rel="noreferrer noopener">7 US Natural Gas Stocks To Watch As Henry Hub Prices Surge 50% In November</a></li>
</ul>

Equities

Mid Cap

ENLC

MLPX

TPYP

ONEOK Bolsters Portfolio With EnLink Acquisition, $4.3 Billion Deal Unveiled

Wedbush analyst Daniel Ives maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Outperform and raises the price target from $325 to $375.

Wedbush Maintains Outperform on Salesforce, Raises Price Target to $375

UHAL

U-Haul Expands Kingsport Operations With Acquisition Of All Season Storage On Fort Henry Drive

JP Morgan analyst Domingos Falavina upgrades Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSBR#NYSE">BSBR</a>) from Neutral to Overweight and lowers the price target from $7 to $6.

BSBR

JP Morgan Upgrades Banco Santander to Overweight, Lowers Price Target to $6

JP Morgan analyst Domingos Falavina downgrades Bank Bradesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBD#NYSE">BBD</a>) from Overweight to Neutral.

JP Morgan Downgrades Bank Bradesco to Neutral

Wedbush analyst Daniel Ives maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Outperform and raises the price target from $57 to $75.

PLTR

Wedbush Maintains Outperform on Palantir Technologies, Raises Price Target to $75

JP Morgan analyst Jeffrey Zekauskas reinstates Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Overweight and announces $76 price target.

BERY

JP Morgan Reinstates Overweight on Berry Global Gr, Announces $76 Price Target

On Friday, November 22, U.S. markets closed higher, with all major indexes recording weekly gains. Optimism was driven by robust U.S. business activity and expectations of interest rate cuts.
However, tech faced pressure as Alphabet fell amid antitrust scrutiny, and Nvidia slipped following a cautious forecast. Investors also weighed geopolitical tensions, including Ukraine-Russia conflicts, and anticipated key developments, such as Trump&#8217;s Treasury Secretary selection.
According to economic data, the S&amp;P Global U.S. Services PMI rose to 57 in November from 55, while Manufacturing PMI edged up to 48.8 from 48.5. However, U.S. consumer sentiment dropped to 71.8, down from a preliminary 73 reading.
Industrials, financials, and consumer discretionary stocks led S&amp;P 500 gains Friday, while utilities and communication services lagged.
The Dow Jones Industrial Average was up 0.97% and closed at 44,296.51, the S&amp;P 500 gained 0.35% to 5,969.30, and the Nasdaq Composite rose 0.16% to finish at 19,003.65.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 gained 1.08% and ended the session at 38,735.00, led by gains in the Chemical, Petroleum &amp; Plastic, Mining and Textile sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.28% and ended the day at 8,417.60, led by gains in the A-REITs, Healthcare, and Consumer Discretionary sectors.</li>
<li>India&#8217;s Nifty 50 rose 1.32% to 24,221.90, and Nifty 500 gained 1.58%, closing at 22,576.60, led by gains in the Oil &amp; Gas, Capital Goods, and Public Sector Undertakings sectors.</li>
<li>China&#8217;s Shanghai Composite declined 0.10% to close at 3,263.76, and the Shenzhen CSI 300 fell 0.46%, finishing the day at 3,848.09.</li>
<li>Hong Kong&#8217;s Hang Seng fell 0.41% and closed the session at 19,150.99.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 index was up 0.35%.</li>
<li>Germany&#8217;s DAX rose 0.45%.</li>
<li>France&#8217;s CAC gained 0.12%.</li>
<li>U.K.&#8217;s FTSE 100 index traded higher by 0.12%</li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.42% at $70.94/bbl, and Brent was down 0.40% at $74.32/bbl.</li>
<li>Oil prices steadied after last week&#8217;s 6% gains, driven by geopolitical tensions involving Russia and Iran. Markets await the OPEC+ meeting and rising Chinese crude demand, while potential U.S. sanctions on Iran threaten supply disruptions.</li>
<li>Natural Gas rose 3.99% to $3.418.</li>
<li>Gold was trading lower by 1.21% at $2,703.90, Silver was down 1.56% to $31.282, and Copper gained 0.67% to $4.1612.</li>
</ul>
U.S. Futures at 06:00 AM ET
Dow futures gained 0.68%, S&amp;P 500 futures were up 0.51% and Nasdaq 100 futures rose 0.61%.
Forex at 06:00 AM ET
The U.S. dollar index fell 0.55% to 106.97, the USD/JPY was down 0.23% to 154.38, and the USD/AUD rose 0.39% to 1.5355.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mixed, Europe Markets Gain While Gold And Dollar Dip - Global Markets Today While US Slept

<ul>
<li>The transaction will be implemented pursuant to a previously announced prearranged chapter 11 plan supported and funded by 100 percent of CareMax's current secured lenders (the "Prearranged Plan"). The sale of the Core Centers' Assets is anticipated to be consummated simultaneously with CareMax's Prearranged Plan.</li>
<li>CareMax has obtained Court approval to maintain business-as-usual operations to ensure the Company's medical centers and physician affiliates continue providing uninterrupted, high-quality care and service to all patients.</li>
</ul>

CMAX

ClareMedica Health Partners Has Entered Into A "Stalking Horse" Purchase Agreement With CareMax To Purchase CareMax's Core Centers' Assets Including A Vast Majority Of CareMax's Operating Clinics

Under the terms of the agreement BXCI will provide EQT $3.5 billion of cash consideration in exchange for a non-controlling common equity interest in the JV.&nbsp;
The investment implies a total JV valuation of approximately $8.8 billion, or 12x EBITDA. The JV provides EQT with a large-scale equity capital solution at an accretive cost of capital.&nbsp;
Additionally, EQT will retain the rights to growth projects associated with the assets contributed to the JV, including the planned Mountain Valley Pipeline ("MVP") expansion and the MVP Southgate project.
EQT plans to use proceeds from this transaction to pay down its term loan and revolving credit facility and redeem and tender for senior notes.&nbsp;
 &nbsp;

EQT Enters Definitive Agreement With Funds Managed By Blackstone Credit & Insurance To Form New $3.5B Midstream Joint Venture

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.gctsemi.com&amp;esheet=54157480&amp;newsitemid=20241125186361&amp;lan=en-US&amp;anchor=GCT+Semiconductor+Holding+Inc.&amp;index=1&amp;md5=b1d413e4a77dc13f33b9a00307a04cc3">GCT Semiconductor Holding Inc.</a> ("GCT" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>), a leading designer and supplier of advanced 5G and 4G semiconductor solutions, announced today the signing of a definitive agreement with a European tier one wireless infrastructure and terminal provider (the "Tier One Supplier") to collaborate on the development of Fixed Wireless Access ("FWA") technology using GCT's 5G solutions including modem chipset and RFIC.
The Company previously announced the signing of an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pressviewer.com%2Fprofiles%2Finvestor%2FNewsPrint.asp%3Fv%3D6%26b%3D2932%26ID%3D137001%26m%3Drl%26g%3D2763&amp;esheet=54157480&amp;newsitemid=20241125186361&amp;lan=en-US&amp;anchor=MOU+with+the+Tier+One+Supplier&amp;index=2&amp;md5=22076aa6120c7cd56d052f4fe151f7b7">MOU with the Tier One Supplier</a> in August 2024, a continuation of an existing key customer relationship now moving to 5G. GCT expects the launch of FWA devices related to this activity to commence in the second half of 2025.
"This collaboration is a major milestone and reinforces the momentum we are gaining in solidifying customer engagement and strengthening client relationships for growth as we prepare for our 5G chipset launch," said John Schlaefer, CEO of GCT. "We look forward to working together on this significant partner's 5G portfolio and high-performing FWA technology."
The growing 5G FWA technology is a cost-effective alternative to traditional wired broadband options and offers reliable connectivity in remote or underserved areas. Based on the Ericsson Mobility Report (June 2024)&#x2A;, the number of 5G FWA connections worldwide is projected to increase over 800% from the end of 2023 to the end of 2029, representing an increase from ~30 million connections to ~280 million connections. With its strong expertise in 5G chip development, GCT is fully prepared to take advantage of this growing market.

Comments

MedBright AI Investments

Notizie

Ultime notizie per MedBright AI Investments (OTC:MBAIF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO